← Russell 3000 cross-section

RGEN REPLIGEN CORP

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$10.3bn
Revenue TTM
$785m
Net income TTM
$42m
Free cash flow
$112m
Composite score
40.9
Sector rank
#702

Valuation

P / E
247.3
EV / EBITDA
EV / sales
12.8
FCF yield
1.09%
Earnings yield vs 10-yr
-4.33pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
5.3%
EBITDA margin
ROE
2.0%
ROIC
3.5%
Revenue growth
15.4%

Insider activity, last 90 days

Net open-market
$-1.16m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of June 30, 2026 and December 31, 2025: During the six months ended June 30, 2026, the Company recognized $ 9.6 million of revenue that was deferred and included within accrued liabilities and other noncurrent liabilities as of December 31, 2025. During the six months ended June 30, 2025, the Company recognized $ 8.5 million of revenue that was deferred and included within accrued liabilities and other noncurrent liabilities as of December 31, 2024. …REPLIGEN CORP, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →